Acurx Pharmaceuticals 的前景乐观：买入评级受到监管里程碑和 Ibezapolstat 临床成功的推动
Matthew Keller has assigned a Buy rating to Acurx Pharmaceuticals, citing a positive opinion from the European Medicines Agency on the Pediatric Investigation Plan for ibezapolstat (IBZ). This regulatory milestone is crucial for its use in children with C. difficile infections and supports upcoming Phase 3 trials. IBZ has demonstrated a 96% Clinical Cure rate in Phase 2 trials, exceeding vancomycin's historical rate. These factors contribute to Keller's optimistic outlook for Acurx Pharmaceuticals.
Matthew Keller has given his Buy rating due to a combination of factors that highlight the promising outlook for Acurx Pharmaceuticals. A key reason is the positive opinion from the European Medicines Agency’s Pediatric Committee on the Pediatric Investigation Plan for ibezapolstat (IBZ), which is a crucial step for its use in children with C. difficile infections. This regulatory milestone is significant as it positions IBZ favorably for its upcoming Phase 3 trials and supports the pathway for future marketing authorization applications in both the EU and the US.
Additionally, IBZ has shown impressive clinical efficacy in previous Phase 2 trials, with a high Clinical Cure rate of 96%, which surpasses the historical cure rate of vancomycin. The success in these trials, coupled with the favorable regulatory feedback, underscores the potential of IBZ as a treatment for C. difficile infections. These developments collectively contribute to Keller’s optimistic outlook and the Buy rating for Acurx Pharmaceuticals.
